Kornimate/medical-research-clean huggingface dataset:
psychological effects of the covid-19 pandemic on the hungarian adult population

Conditions: Questionnaire Designs; COVID-19 Pandemic; Psychological Stress; Coping Skills; Two-Item Generalised Anxiety Disorder Scale; Patient Health Questionnaire Anxiety and Depression Scale; Health Status Index; Subjective Health Complaint; Mood

Summary: the aim of the study is to explore the psychological effects of the covid-19 pandemic among hungarian adults with the use of an anonymous online questionnaire that consists of 65 items. with these results it will possible to identify coping strategies that can help hungarian adults to deal with the difficulties arising from the pandemic.

planned course of the project: 1. we make the questionnaire using google forms. 2. the link of the online questionnaire is sent to three public groups via the social media website facebook. 3. by clicking on the sent link, all participants are able to read information about the project and about the consent to participate in it. then the participant will be able to give consent to participate in the project. after giving consent, the participant will be able to start filling out the questionnaire. if the participant indicates that he/she does not want to give consent to the study, the website will indicate that the participation of him/her has ended in the project. 4. anonymous answers will be automatically saved. 5. the participants will be given code numbers based on the order in which they filled out the questionnaire. 6. the data will be analysed by the researchers. for a participant, completing the online questionnaire takes approximately 10-15 minutes.

Eligibility criteria:
inclusion criteria: the participant must have access to the internet and to the social media website facebook. exclusion criteria: none
dietary calcium intake in premenstrual syndrome

Conditions: Premenstrual Syndrome

Summary: this study was planned and conducted to investigate effect of adequate calcium intake on premenstrual syndrome (pms) symptoms in women with pms who have inadequate calcium intake.

this study was planned and conducted to investigate effect of adequate calcium intake on premenstrual syndrome (pms) symptoms in women with pms who have inadequate calcium intake. thirty one women, aged between 20-28 years, diagnosed with pms and suitable for inclusion criteria, were participated in study. participants were allocated to intervention (n=16) and control (n=15) groups randomly.

Eligibility criteria:
inclusion criteria: women with; * pms who have inadequate calcium intake * regular menstrual cycle * menstrual flow which occurs every 22 to 35 days and last three to eight days exclusion criteria: * having any of metabolic diseases * use oral contraceptive pill * user vitamins and minerals supplements * being smoker

Keywords: premenstrual syndrome calcium quality of life
bariatric surgery and pharmacokinetics of enalapril

Conditions: Obesity, Morbid

Summary: changes to gastric ph, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. these factors are potentially influenced by bariatric surgery. little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. in this study the pharmacokinetic effects of bariatric surgery on enalapril are investigated.


Eligibility criteria:
inclusion criteria: * preparing to undergo gastric bypass or sleeve gastrectomy in central norway * being a norwegian citizen exclusion criteria: * having previously undergone resections in the gi-tract

Keywords: bariatric surgery gastrointestinal tract biological availability pharmacokinetics enalapril
nasal swab home collection kit (nshc kit) study

Conditions: Influenza Viral Infections

Summary: the purpose of this study is to demonstrate that persons over the age of 13 years can obtain a self-collected nasal swab reliably and safely for subsequent use in the diagnosis of influenza. similarly, the purpose is to demonstrate that parents or guardians can safely and effectively collect nasal swab specimens from children, ages 0 through 12 years, and others needing assistance in doing so, and that these parent/guardian-collected nasal swabs can also be used in the diagnosis of influenza. clinical performance of the swabs will be based on the comparison of the performance of the nasal swab that is self- or parent/guardian-collected to one collected from the same specimen donor by a skilled clinical coordinator and used in clia (clinical laboratory improvement amendments)-waived, rapid diagnostic test called sofia influenza a+b fia (fluorescence immunoassay analyzer).


Eligibility criteria:
inclusion criteria: * fever * nasal congestion * rhinorrhea * sore throat * cough exclusion criteria: * unable to read and understand or refusal to sign the appropriate informed consent/assent forms * refusal to complete the patient's demographic and medical history * treatment with anti-influenza antivirals within the previous 7 days * vaccinated by means of an influenza nasal spray/mist vaccine within the previous 7 days.
exercise in dialysis

Conditions: Depression

Summary: the purpose of the proposed clinical trial is to support intradialytic pedal cycling exercise as an intervention and show its effect on depression and how there is a need for more programs to support this. this is an exploratory single arm study. these patients will be cycling during dialysis treatment by using a graded duration model. even though patients on hemodialysis (hd) have an increased life span due to renal replacement therapy, exercise can have a remarkable effect on their ability to perform daily activities. dialysis has been shown to reduce self-confidence, increase social isolation, and cause feelings of disappointment in the future. this population faces mental and psychological stress due to the disease burden. short-term supervised cycling programs while patients are receiving dialysis have been reported to induce systematic improvements for depression and anxiety. exercise during hemodialysis is an effective way to reduce depressive symptoms without using pharmacologic measures. data for each patient will be collected at each dialysis treatment using a unique patient identifier. the data that will be collected include duration of exercise (intermittent or continuous), any complications during hd, vital signs while cycling every 30 minutes, and how they state they feel after cycling. the measurable outcome will be depression scores. the tool that will be used for this project is the beck depression inventory (bdi). the patient will complete the bdi assessment on week 1 (pre intervention as baseline) and then on week 10 (post intervention).


Eligibility criteria:
inclusion criteria: 1. greater than 18 years of age 2. male or female 3. eskd on maintenance hemodialysis for 3 consecutive months 4. adequate dialysis clearances (kt/v greater than 1.2), 5. able to participate in exercise program based on nephrologist evaluation 6. able to provide written informed consent for participation, 7. compliance with dialysis treatment regimen (attended 75% of ordered dialysis treatments in the last 3 months. exclusion criteria: 1. less than 18 years old 2. on hemodialysis for \< 3 consecutive months 3. acute kidney injury diagnosis 4. patients deemed clinically unstable by nephrologist 5. active foot ulcer 6. unable to provide written consent 7. refusal of participation 8. lower limb amputations 9. patients with dementia or severe cognitive impairment 10. patients with psychiatric disorders (who are not treated and unstable) 11. pregnancy 12. myocardial infarction in the last 6 months 13. uncontrolled diabetes 14. patients on chronic midodrine therapy for intradialytic blood pressure support. 15. deep vein thrombosis 16. symptomatic peripheral vascular disease and/or recent lower extremities vascular intervention (i.e. bypass)

Keywords: hemodialysis
effect of apelin on insulin sensitivity in type 2 diabetic volunteers

Conditions: Diabetes

Summary: preclinical studies have demonstrated in mouse models that (pyr1)-apelin-13 exerts a glucose-regulating action in vivo. the (pyr1)-apelin-13 effect on insulin sensitivity in healthy overweighed volunteers has been previously assessed in a phase i clinical trial (apelins study; nct02033473). the apelins-2 clinical trial aims to expand the initial proof of concept to the population targeted by future innovative insulin-sensitizing therapies: patients living with type 2 diabetes.

insulin sensitivity is measured using the hyperinsulinemic euglycemic glucose clamp method. the hypothesis of the investigators is that a continuous (pyr1)-apelin-13 infusion improves insulin sensitivity of type 2 diabetic patients compared to placebo infusion. this study could bring new elements for understanding the pathophysiology of insulin resistance and type 2 diabetes mellitus in humans and could lead to the development of innovative therapies in type 2 diabetes mellitus.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of type2 diabetes * body mass index between 27 and 33 kg / cm ² * hba1c \< 8.5% * non-pathological electrocardiogram * heart rate between 50 and 80 beats per minute at rest. * complete blood count (cbc) with no significant anomaly in terms of the investigator.. * serum electrolytes without clinically significant abnormalities in terms of the investigator. * liver function tests without clinically significant abnormalities in terms of the investigator * renal function tests without clinically significant abnormalities in terms of the investigator * good peripheral vein (forearm and back of the hand). * agreement to participate in the establishment of a serum bank. * ability to sign informed consent. * affiliation to a social security scheme exclusion criteria: * secondary prevention of cardio-vascular disease * insulin therapy or glucagon like peptid 1 (glp-1) analogs therapy in the 6 months before inclusion. * risk factor, treatment or electrocardiogram as recommended by international conference on harmonization (ich) e14 "clinical evaluation of qt / qtc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs" * repeated a qtc interval\> 450 ms measurement * risk factor for torsade de pointes: myocardial infarction, hypokalemia, family history of long qt syndrome * personal history of cancer. * positive hiv serology. * hepatitis b serology positive. * positive hepatitis c serology. * cognitive impairment or mental illness (at the discretion of the investigator). * chronic excessive alcohol consumption (consumption \> 30g/day or 210g/week). * person under judicial protection, guardianship. * subject with a resting systolic blood pressure greater than 140 mm hg and diastolic blood pressure greater than 90 mmhg * smoking more than 10 cigaret per day and can not be interrupted for 24 hours.

Keywords: type 2 diabetic volunteers
mobile health application to improve patient satisfaction after urethroplasty

Conditions: Urethral Stricture

Summary: create a custom urethroplasty mobile application that will guide patients through through the surgical process.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * have a urethral stricture and are under going urethroplasty surgery exclusion criteria: * patients that do not have mobile phone capabilities * patients who have physical or cognitive impairment when using a mobile phone or answering questionnaires * inability to provide consent to the study
prostatic artery embolization vs. pharmacotherapy for luts/bph

Conditions: Benign Prostatic Hyperplasia; Pharmacotherapy; Prostatic Artery Embolization; Minimally Invasive Treatment

Summary: this study compares safety and efficacy of prostatic artery embolization and pharmacotherapy in the treatment of lower urinary tract symptoms associated wit benign prostatic hyperplasia.


Eligibility criteria:
inclusion criteria: * men ≥45 years of age * lower urinary tract symptoms assigned to bph (diagnosis by medical history and physical examination) * ipss ≥ 8 points * qol ≥ 3 points * qmax ≤ 15 ml/s with a minimum voided volume ≥ 125 ml * informed consent for study participation exclusion criteria: * renal impairment (gfr \< 30ml/min) * previous prostatic surgery * 5-alpha reductase inhibitor (5-ari) use within 6 mo (or dutasteride within 12 mo) prior to entry, or use of an α-blocker or phytotherapy for bph within 2 weeks prior to entry * history or evidence of prostate cancer * absolute indication for surgical treatment of complications related to bph (i.e. bladder stones, renal impairment due to bladder outlet obstruction) * history of neurogenic bladder dysfunction * not able to complete questionnaires due to cognitive or thought disorders * language skills insufficient for informed consent and / or completion of questionnaires
primary palliative care in heart failure: a pilot trial

Conditions: Heart Failure

Summary: patients with advanced heart failure (hf) typically experience significant burdens that negatively impact their quality of life. although palliative care has been shown to improve patient outcomes in other serious illnesses, insufficient data exist to support its use in hf. furthermore, the demand for palliative care in serious illness outstrips the available supply of certified palliative care clinicians. this pilot trial will assess the feasibility and acceptability of training cardiology nurses in basic palliative care skills and their ability to deliver this care alongside usual hf management.

patients with advanced heart failure (hf) suffer from significant pain, fatigue, difficulty breathing, anxiety, and depression. palliative care (pc) is a medical specialty designed to focus on relieving patient suffering by providing an extra layer of support on top of usual care. to date, there has been little research on the impact of pc in hf. we will conduct a randomized clinical trial to assess the feasibility, acceptability, and perceived effectiveness of training cardiology nurses in pc and administering pc to their patients. patients will be randomized into either the usual care group or the intervention group. usual care participants will receive their care with no alterations, and intervention participants will receive the pc intervention from their nurse on top of their usual care. both groups will complete health-related surveys on tablet computers, via email, and/or via telephone. in the intervention group, these answers will be used to tailor the intervention to the specific patient's needs. caregivers will also be recruited into the study, and will complete surveys similar to the patients via the aforementioned methods.

Eligibility criteria:
inclusion criteria: * new york heart association class iii or iv heart failure * 2 or more hospitalizations in the past year due to heart failure exclusion criteria: * less than 40 years old * currently awaiting a transplant * received outpatient palliative care within the past 12 months * pregnant or intends to be within the next 12 months * no regular phone access * not fluent in english * failed the callahan 6-item screener * does not intent to regularly attend clinic for the next 12 months

Keywords: palliative care
study of veltuzumab (ha20) at different doses in patients with itp

Conditions: Purpura, Thrombocytopenic, Idiopathic; Autoimmune Thrombocytopenic Purpura; Purpura, Thrombocytopenic, Autoimmune

Summary: this trial will study different dose levels of ha20 (immu-106) to see if they are safe and effective for treating itp.

the goal of current treatment guidelines for most patients with chronic adult itp is to maintain platelet levels above 30 x 109/l. the conventional first-line therapy is corticosteroids with or without intravenous immunoglobulins, but many patients relapse when steroids are tapered. standard therapy then is splenectomy, but patients with refractory itp who do not respond require further therapy. unfortunately, immunosuppressive agents or other available treatments typically produce only short-term responses. because of the lack of medical options after first-line therapy, the target population for this first study of anti-cd20 immunotherapy with ha20 are adult patients with chronic itp who failed at least one standard itp therapy (i.e., received at least one standard itp therapy and now present with platelet levels below 30 x 109/l). in autoimmune disease, rituximab as well as other anti-cd20 antibodies currently being considered for commercialization have focused on a different dosing schedule in rheumatoid arthritis, and use fixed dosages rather than variable doses based on body surface area. in addition, recent studies of these newer anti-cd20 antibodies in rheumatoid arthritis have reported that lower doses indeed appear effective when administered twice, 2 weeks apart. based upon these considerations, patients in this study will receive ha20 twice, 2 weeks apart, and administered at one of 3 dose levels.

Eligibility criteria:
inclusion criteria: * male or female, \>18 years old, with or without prior splenectomy * signed written informed consent obtained prior to study entry * itp according to ash guidelines, with other potential causes of thrombocytopenia excluded * platelet levels \< 150 x 109/l for more than 6 months * received an adequate course of at least one standard itp treatment (an inadequate course of standard itp therapy does not qualify as meeting this requirement) * platelet count \ 10 x 109/l at study entry). * bleeding assessment score of grade 0 or 1. see full protocol for all inclusion criteria exclusion criteria: see full protocol for exclusion criteria or contact study staff for details

Keywords: itp ha20 treatment
knowledge base in the treatment of atopic dermatitis among thai pediatricians

Conditions: Childhood Atopic Dermatitis

Summary: the purpose of this study is to determine knowledge base in diagnosis, investigation and treatment of pediatric atopic dermatitis among thai pediatricians.

background: currently, there is no existing information regarding prescribing practices for the management of childhood atopic dermatitis among pediatricians in thailand. objective: in order to learn about basic knowledge, natural history, evaluation, diagnosis, treatment and prevention for childhood atopic dermatitis in thailand methods: 900 self-administered questionnaires were randomly mailed to pediatricians throughout thailand, asking about their preferences in the management of childhood atopic dermatitis. one hundred and eighty-five of these 900 questionnaires were returned (a response rate of 20.6%)

Eligibility criteria:
inclusion criteria: * all pediatricians who're working in thailand including sub-board pediatricians.

Keywords: atopic dermatitis thai pediatricians
safety and efficacy study of pilocarpine hcl ophthalmic solution in participants with presbyopia

Conditions: Presbyopia

Summary: a study to evaluate the efficacy, safety, and pharmacokinetics of pilocarpine hcl ophthalmic solution when administered bilaterally, once daily for 30 days in participants with presbyopia.


Eligibility criteria:
inclusion criteria: * 1 participant must be 40 to 65 years of age inclusive, at the time of the screening visit; * 2 emmetropes or non-emmetropes with best distance correction in the range of spherical -4.00 d to +2.00 d inclusively and cylinder ±2.00 d with photopic, high contrast cdva of 20/25 or better in each eye at the screening and baseline visits; * 3 mesopic, high contrast dcnva of 20/40 to 20/100 in each eye at the screening and baseline visits; * 4 photopic, high contrast, near visual acuity correctable to 20/40 or better in each eye at the screening and baseline visits; * 5 dark adaptation pupil diameter between 4.0 mm and 8.0 mm in both eyes at the screening visit; * 6 capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the icf and in this protocol. exclusion criteria: * 1 clinically significant disease state, in the opinion of the examining investigator or designee, in any body system; * 2 known allergy or sensitivity to the study intervention or its components or other cholinergic agonist medications; * 3 any active ocular inflammation within 30 days prior to the first use of the investigational drug; * 4 current enrollment in an study or participation in such a study within 30 days prior to the first use of the investigational drug; * 5 any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation, or excretion; * 6 history of cataract surgery, phakic intraocular lens surgery, corneal refractive surgery, radial keratotomy, or any intraocular surgery; * 7 presence of any ocular condition that, in the opinion of the investigator, could affect the safety of the participant or interpretation of efficacy parameters; * 8 moderate to severe dry eye disease at the screening visit; * 9 lens opacity in either eye that is determined to cause significant disturbance of the central visual axis at the screening visit; * 10 diagnosis of any type of glaucoma or ocular hypertension; * 11 female who have a positive pregnancy test during the screening period, lactating, or planning a pregnancy during the study.
the impact of pediatric skin disorders: the "big" study

Conditions: Chronic Pediatric Skin Conditions

Summary: this study leverages the availability of a validated series of instruments to measure the effect of highly visible, chronic skin disorders, including atopic dermatitis (ad), on patients 8 years of age and above in causing stigma and psychiatric issues, particularly anxiety and depression.

this is a multi center study with northwestern university/lurie children's hospital serving as the data coordinating center. site selection has been completed through members of pedra.

Eligibility criteria:
inclusion criteria: * subjects must be aged 8-17 years of age * subject must be diagnosed with a chronic skin disease deemed to be severe enough and/or in a visible location that could be stigmatizing as determined by the study doctor * subject and parent must both be english speaking with at least one parent/guardian who will complete the questionnaires * subject and parent/guardian must be able to complete the relevant questionnaires exclusion criteria: * children under 8 years of age * children with developmental delay and/or a behavioral disorder that would preclude participation in form completion * children with a non-cutaneous disorder that is considered by the study doctor to be stigmatizing